Kyverna Therapeutics Announces Publication of Registrational Miv-cel Data in Patients with Stiff Person Syndrome in JAMA Neurology

Kyverna Therapeutics announced the publication of KYSA-8 registrational trial data for miv-cel in stiff person syndrome (SPS) in JAMA Neurology. The single-dose CAR T-cell therapy demonstrated statistically significant improvements across all primary and secondary endpoints at 16 weeks, with 67% of patients requiring walking aids at baseline no longer needing them. All patients discontinued chronic immunotherapies, and the therapy showed a well-tolerated safety profile with no high-grade adverse events.